7D2A Stock Overview A medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sedana Medical AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Sedana Medical Historical stock prices Current Share Price SEK 1.44 52 Week High SEK 2.39 52 Week Low SEK 0.88 Beta 0.33 1 Month Change 34.83% 3 Month Change -32.08% 1 Year Change -26.31% 3 Year Change -81.64% 5 Year Change -55.56% Change since IPO -26.75%
Recent News & Updates
New minor risk - Market cap size Nov 17
Independent Chairman of the Board recently bought €127k worth of stock Nov 06
Supply Chain & Manufacturing Director recently bought €13k worth of stock Oct 30
New minor risk - Profitability Oct 29
No longer forecast to breakeven Oct 29
Third quarter 2024 earnings released: kr0.22 loss per share (vs kr0.069 loss in 3Q 2023) Oct 25 See more updates
New minor risk - Market cap size Nov 17
Independent Chairman of the Board recently bought €127k worth of stock Nov 06
Supply Chain & Manufacturing Director recently bought €13k worth of stock Oct 30
New minor risk - Profitability Oct 29
No longer forecast to breakeven Oct 29
Third quarter 2024 earnings released: kr0.22 loss per share (vs kr0.069 loss in 3Q 2023) Oct 25 Sedana Medical AB (publ) to Report Q1, 2025 Results on May 06, 2025
Second quarter 2024 earnings released: kr0.17 loss per share (vs kr0.014 profit in 2Q 2023) Jul 24 Sedana Medical AB (publ) (OM:SEDANA) agreed to acquire Innovatif Cekal Sdn. Bhd. for SEK 35 million. Jul 23
Less than half of directors are independent Jun 02
Sedana Medical AB (publ) Completes Patient Recruitment for its Clinical Program in the US May 29
First quarter 2024 earnings released: EPS: kr0.21 (vs kr0.16 loss in 1Q 2023) Apr 26
Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US Apr 25
Ola Magnusson and Eva Walde Decline Re-Election as Board Members of Sedana Medical AB (publ) Apr 23
Full year 2023 earnings released: kr0.60 loss per share (vs kr0.74 loss in FY 2022) Apr 17
Full year 2023 earnings released: kr0.60 loss per share (vs kr0.74 loss in FY 2022) Feb 16
Forecast to breakeven in 2026 Feb 16
Sedana Medical AB (publ) Files Submission for Paediatric Indication Dec 20
Sedana Medical Secures Data Exclusivity and Market Protection for Sedaconda (isoflurane) Until 2031 Nov 22
Sedana Medical AB (Publ) Announces the Main Results from the Paediatric Isocomfort Study Nov 17
Chief Medical Officer recently bought €76k worth of stock Nov 02 Sedana Medical AB (publ), Annual General Meeting, May 22, 2024
Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.075 loss in 3Q 2022) Oct 27
Sedana Medical AB (publ) Announces Completion of Enrollment Oct 23
Sedana Medical AB (publ) Announces Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for Sedaconda (Isoflurane) in United Kingdom Oct 10
Chief Financial Officer recently bought €154k worth of stock Sep 28
No longer forecast to breakeven Aug 15
New minor risk - Profitability Jul 25
Second quarter 2023 earnings released: EPS: kr0.01 (vs kr0.11 loss in 2Q 2022) Jul 21
New minor risk - Profitability Jul 14
Sedana Medical AB (publ) Informs About Adjusted US Submission Plan Following FDA Interaction Jul 12
Sedana Medical AB (Publ) Announces Thomas Eklund Decline Re-Election May 17
Full year 2022 earnings released: kr0.74 loss per share (vs kr0.63 loss in FY 2021) Apr 08
Full year 2022 earnings released: kr0.74 loss per share (vs kr0.63 loss in FY 2021) Feb 17
Sedana Medical AB (publ) Receives Market Approval for Sedaconda in Italy Feb 07
Sedana Medical AB (publ) to Report Fiscal Year 2022 Final Results on Apr 03, 2023 Jan 31
Sedana Medical AB (publ) Completes Patient Recruitment for Pediatric IsoCOMFORT Study Jan 10
Sedana Medical Receives FDA Fast Track Designation in the United States Jan 04 Sedana Medical Receives Positive Opinion from Ema's Pediatric Committee on Reduced Pediatric Study Design
No longer forecast to breakeven Nov 16
No longer forecast to breakeven Oct 30
Third quarter 2022 earnings released: kr0.08 loss per share (vs kr0.16 loss in 3Q 2021) Oct 26 Sedana Medical AB (publ) to Report Q1, 2023 Results on Apr 27, 2023
Second quarter 2022 earnings released: kr0.11 loss per share (vs kr0.19 loss in 2Q 2021) Jul 22
Sedana Medical AB (publ) Approves Board Changes May 12
Forecast breakeven date pushed back to 2024 Apr 30
First quarter 2022 earnings released: kr0.19 loss per share (vs kr0.097 loss in 1Q 2021) Apr 29 Sedana Medical Announces Enrolment of First Patient in US Clinical Program Apr 28
Full year 2021 earnings released: kr0.63 loss per share (vs kr0.30 loss in FY 2020) Apr 09
Forecast breakeven date pushed back to 2023 Mar 10
Forecast breakeven date pushed back to 2023 Mar 04
Forecast breakeven date moved forward to 2022 Mar 01
Forecast breakeven date pushed back to 2023 Feb 19
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 18 Sedana Medical AB (publ) to Report Q1, 2022 Results on Apr 28, 2022
Sedana Medical AB (publ), Annual General Meeting, May 11, 2022 Feb 17
Sedana Medical AB (publ) to Report Q4, 2021 Results on Feb 17, 2022 Feb 10
Forecast to breakeven in 2022 Jan 25
Sedana Medical Receives Investigational New Drug Approval for US Trials Dec 24
Sedana Medical AB Applies for Market Approval in Italy Dec 23
Independent Director recently sold €97k worth of stock Dec 10
Sedana Medical AB (publ) Submits IND for U.S Clinical Trials Nov 24
Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.15 loss in 3Q 2020) Nov 07
Independent Director recently sold €289k worth of stock Sep 25
Forecast to breakeven in 2022 Sep 23
Second quarter 2021 earnings released: kr0.19 loss per share (vs kr0.039 loss in 2Q 2020) Aug 21
Sedana Medical Receives Approval in France Aug 13
Independent Director has left the company May 20
First quarter 2021 earnings released: kr0.39 loss per share (vs kr0.075 profit in 1Q 2020) May 07
Full year 2020 earnings released: kr1.19 loss per share (vs kr0.78 loss in FY 2019) Apr 17
Full year 2020 earnings released: kr1.19 loss per share (vs kr0.78 loss in FY 2019) Mar 02
Revenue beats expectations Mar 02 Sedana Medical AB (publ) Announces Resignation of Its CEO Christer Ahlberg
Sedana Medical AB (publ) Announces Inclusion of First Patient in Pediatric Study IsoCOMFORT Feb 23
Sedana Medical AB (publ) Submits Application for Market Approval in UK Feb 20
New 90-day high: €36.55 Feb 16
New 90-day high: €35.75 Jan 28
Sedana Medical Submits Application for Marketing Approval in Switzerland Jan 22
New 90-day high: €35.40 Jan 06
New 90-day high: €27.85 Dec 10
Sedana Medical AB (publ) to Report Q3, 2021 Results on Nov 04, 2021 Dec 04 Shareholder Returns 7D2A DE Medical Equipment DE Market 7D -14.8% 1.0% 1.7% 1Y -26.3% -8.3% 9.4%
See full shareholder returns
Return vs Market: 7D2A underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is 7D2A's price volatile compared to industry and market? 7D2A volatility 7D2A Average Weekly Movement 16.4% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7D2A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7D2A's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; and Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care, as well as AnaConDa, a medical device enabling administration of inhaled anaesthetics. It also provides FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; Scavenging tube, a one piece pre-connected tube designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; FlurAbsorb mount to hold the FlurAbsorb during scavenging of anesthetic gas; FlurAbsorb-S mount to hold the FlurAbsorb-S during scavenging of anesthetic gas; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and Mindray exhaust connector, which enables to connect the exhaust of the ventilator to an active or passive scavenging system.
Show more Sedana Medical AB (publ) Fundamentals Summary How do Sedana Medical's earnings and revenue compare to its market cap? 7D2A fundamental statistics Market cap €141.62m Earnings (TTM ) -€4.98m Revenue (TTM ) €15.14m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7D2A income statement (TTM ) Revenue SEK 174.14m Cost of Revenue SEK 51.20m Gross Profit SEK 122.95m Other Expenses SEK 180.19m Earnings -SEK 57.24m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) -0.58 Gross Margin 70.60% Net Profit Margin -32.87% Debt/Equity Ratio 0%
How did 7D2A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 04:12 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sedana Medical AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Östling Pareto Securities Filip Wiberg Pareto Securities Oscar Bergman Redeye
Show 0 more analysts 
